Pharmazz Inc
- Biotech or pharma, therapeutic R&D
Pharmazz has two FDA-approved Phase III INDs and one approved Phase II IND of first-in-class drug candidates. Sovateltide (for treatment of acute cerebral ischemic stroke) and Centhaquine (for treatment of hypovolemic shock). Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin. Sun Pharmaceutical Industries Ltd. is investing USD 25 million for a minority stake in Pharmazz. This strategic investment is to support the completion of Pharmazz's pivotal Phase 3 study for Sovateltide to treat patients with cerebral ischemic stroke.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}